Innovative Drug
Developing Novel Antibody Biologics to Address Unmet Medical Needs
Prestige Biopharma invests its expertise and resources in the development of first-in-class antibody therapeutics to fight life-threatening diseases. To bring innovation for life, we are developing novel monoclonal and bispecific antibody drugs that that contributes to unmet medical needs.
PBP1510
PBP1710
IDC001
IDC005
: Highly aggressive tumors such as pancreatic cancer often feature extensive development of connective tissue, known as desmoplasia, and rapid growth of blood and lymphatic vessels, referred to as angiogenesis and lymph-angiogenesis. These processes are co-dependent. IDC005 is a bispecific antibody that targets desmoplasia and (lymph-)angiogenesis.
IDC007
: Systemic inflammatory response syndrome (SIRS) is a severe, often fatal cascade of exaggerated immune responses. It can be caused by infectious and autoimmune diseases such as COVID-19 and lupus, and immunotherapies like T-cell based therapies and immune checkpoint inhibitors. IDC007 is a bispecific antibody that suppresses two key molecules in the development of CRS.
IDC008
: More than 80% of cancer patients do not respond to treatment by immune checkpoint inhibitors, which is a challenge seen in tumors with severely immune-suppressed tumor microenvironment (TME). Another challenge is that some patients are susceptible to the drugs’ off-target adverse effects. IDC008 is a bispecific antibody that targets PAUF and an immune checkpoint molecule expressed in tumors. Targeting PAUF increases the selectivity of the immune checkpoint inhibition and alleviates TME immune suppression, at the same time.
Our groundbreaking accomplishments
Pipeline
Indication
Development Stage
First-in-class
PBP1510
Ulenistamab
Pancreatic cancer, Ovarian Cancer
Clinical (Phase 1/2a)
PBP1710
Solid tumor
Preclinical
IDC111
Solid tumor
Basic Research
Bispecific Antibody
IDC001
Solid tumor
Basic Research
IDC002
Solid tumor
Basic Research
IDC003
Solid tumor
Basic Research
IDC005
Solid tumor
Discovery
IDC007
Critical immune disorders
Discovery
IDC008
Solid tumor
Discovery
IDC009
Solid tumor
Discovery
IDC010
Immune disease
Discovery
Novel Concept Antibody
IDC331
Solid tumor
Discovery
IDC332
Solid tumor
Discovery
IDC333
Solid tumor
Discovery
IDC334
Solid tumor
Discovery
Antibody Drug Conjugate
IDC441
Solid tumor
Basic Research
Diagnostic Kit
IDC221
Pancreatic cancer
Basic Research
First-in-class
PBP1510
Ulenistamab
Indication | Development Stage |
Pancreatic cancer, Ovarian Cancer | Clinical (Phase 1/2a |
PBP1710
Indication | Development Stage |
Solid tumor | Preclinical |
IDC111
Indication | Development Stage |
Solid tumor | Basic Research |
Bispecific Antibody
IDC001
Indication | Development Stage |
Solid tumor | Basic Research |
IDC002
Indication | Development Stage |
Solid tumor | Basic Research |
IDC003
Indication | Development Stage |
Solid tumor | Basic Research |
IDC005
Indication | Development Stage |
Solid tumor | Discovery |
IDC007
Indication | Development Stage |
Critical immune disorders | Discovery |
IDC008
Indication | Development Stage |
Solid tumor | Discovery |
IDC009
Indication | Development Stage |
Solid tumor | Discovery |
IDC010
Indication | Development Stage |
Immune disease | Discovery |
Novel Concept Antibody
IDC331
Indication | Development Stage |
Solid tumor | Discovery |
IDC332
Indication | Development Stage |
Solid tumor | Discovery |
IDC333
Indication | Development Stage |
Solid tumor | Discovery |
IDC334
Indication | Development Stage |
Solid tumor | Discovery |
Antibody Drug Conjugate
IDC441
Indication | Development Stage |
Solid tumor | Basic Research |
Diagnostic Kit
IDC221
Indication | Development Stage |
Pancreatic cancer | Basic Research |